Regulus Therapeutics Inc (NAS:RGLS)
$ 1.61 -0.03 (-1.83%) Market Cap: 105.45 Mil Enterprise Value: 18.63 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 39/100

Q3 2021 Regulus Therapeutics Inc Earnings Call Transcript

Nov 10, 2021 / 10:00PM GMT
Release Date Price: $4.37 (-5.58%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Regulus Therapeutics Inc. Quarter 3, 2021 Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded. I'd now like to turn the conference over to your host, Ms. Cris Calsada, Chief Financial Officer. You may begin.

Cris Calsada

Thanks, operator. Good afternoon, and thank you for joining us to discuss Regulus Therapeutics Third Quarter 2021 financial results and corporate highlights. With me on today's call is Jay Hagan, President and Chief Executive Officer; and Denis Drygin, Chief Scientific Officer. Jay will provide opening remarks and share progress on our ADPKD program and I will review the financial results before we open the lines for questions.

Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Regulus' Therapeutic's future expectations plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot